Evaluating the effect of atorvastatin on kidney stone.

Not Applicable

Conditions: Calcium kidney stone.
Calculus of kidney

Registration Number: IRCT2017021826406N2

Lead Sponsor: rology and Nephrology Research Center, Shahid Beheshti University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 30

Inclusion Criteria

History of calcium kidney stone (stone should be radio-opaque in radiological evaluation); at least 2 times of kidney stone episodes (Recurrent stone); at least 20 days since the last treatment; age 18 to 65 years; Hyperoxaluria (24-hour urine oxalate over 40 and less than 80 mg); willingness to cooperate in the study.

Exclusion criteria: Primary or enteric hyperoxaluria (urine oxalate>80 mg/24h);taking any drugs or supplements with antioxidant or anti-inflammatory effects (e.g. steroids, Nonsteroidal Antiinflammatory Drugs, pioglitazone, …), multivitamins containing vitamin A,C or E and any supplement containing anti-oxidants; History of diabetes mellitus, hepatic failure, thyroid or parathyroid diseases, cancers or immunologic diseases, chronic kidney disease (Glomerular filtration rate< 60), Urinary tract infection and chronic diarrhea; Pregnancy or lactation

Exclusion Criteria

Not provided

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
rine malondialdehyde. Timepoint: Before the intervention, 3 months after the intervention. Method of measurement: colorimetric method using Thiobarbituric acid.;Urine neutrophil gelatinase-associated lipocalin. Timepoint: Before the intervention, 3 months after the intervention. Method of measurement: ELISA.

Secondary Outcome Measures